According to documents submitted to the U.S. Securities and Exchange Commission (SEC), AbbVie recorded up to $291 million in "purchased in-process research and development" (IPR&D) expenses in its second quarter 2026 financial results.

This one-time expense had a significant impact on the company's financial metrics, specifically resulting in a reduction of $0.17 in both diluted earnings per share (EPS) calculated according to U.S. Generally Accepted Accounting Principles (GAAP) and adjusted diluted EPS. IPR&D purchase costs are usually associated with acquisition transactions and refer to payments made to acquire intangible assets still in the research and development phase, which have not yet been commercialized. The recognition of this substantial expense directly dragged down AbbVie's profit performance for the quarter. Although this is a non-cash, non-recurring item, it clearly demonstrates the company's proactive investment in strengthening its R&D pipeline through external acquisitions. Investors need to pay attention to the impact of such adjustments when evaluating the company's core operating performance.